1. Home
  2. AMPH vs INBX Comparison

AMPH vs INBX Comparison

Compare AMPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$18.13

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$109.94

Market Cap

999.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
INBX
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
999.7M
IPO Year
2005
2024

Fundamental Metrics

Financial Performance
Metric
AMPH
INBX
Price
$18.13
$109.94
Analyst Decision
Buy
Buy
Analyst Count
8
3
Target Price
$28.38
$150.00
AVG Volume (30 Days)
586.8K
588.0K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$719,887,000.00
$1,300,000.00
Revenue This Year
$6.90
N/A
Revenue Next Year
$4.64
N/A
P/E Ratio
$129.43
N/A
Revenue Growth
N/A
550.00
52 Week Low
$16.65
$12.80
52 Week High
$31.26
$155.29

Technical Indicators

Market Signals
Indicator
AMPH
INBX
Relative Strength Index (RSI) 39.99 50.04
Support Level $17.03 $69.30
Resistance Level $20.08 $153.14
Average True Range (ATR) 0.89 13.35
MACD -0.30 -3.80
Stochastic Oscillator 19.29 21.04

Price Performance

Historical Comparison
AMPH
INBX

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: